Selected article for: "adult onset and high mortality"
Author: Ruscitti, Piero; Berardicurti, Onorina; Di Benedetto, Paola; Cipriani, Paola; Iagnocco, Annamaria; Shoenfeld, Yehuda; Giacomelli, Roberto
Title: Severe COVID-19, Another Piece in the Puzzle of the Hyperferritinemic Syndrome. An Immunomodulatory Perspective to Alleviate the Storm
  • Cord-id: 1s6wtj25
  • Document date: 2020_5_28
    • ID: 1s6wtj25
    Snippet: The coronavirus disease 2019 (COVID-19), an acute respiratory disease caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), has been declared as a worldwide public health emergency. Interestingly, severe COVID-19 is characterized by fever, hyperferritinemia, and a hyper-inflammatory process with a massive release of pro-inflammatory cytokines, which may be responsible for the high rate of mortality. These findings may advocate for a similarity between severe COVID-19 and some c
    Document: The coronavirus disease 2019 (COVID-19), an acute respiratory disease caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), has been declared as a worldwide public health emergency. Interestingly, severe COVID-19 is characterized by fever, hyperferritinemia, and a hyper-inflammatory process with a massive release of pro-inflammatory cytokines, which may be responsible for the high rate of mortality. These findings may advocate for a similarity between severe COVID-19 and some challenging rheumatic diseases, such as adult onset Still's disease, secondary hemophagocytic lymphohistiocytosis, and catastrophic anti-phospholipid syndrome, which have been included in the “hyperferritinemic syndrome” category. Furthermore, as performed in these hyper-inflammatory states, severe COVID-19 may benefit from immunomodulatory therapies.

    Search related documents:
    Co phrase search for related documents
    • aberrant immune response and acute respiratory sars syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • aberrant immune response and low mortality: 1
    • aberrant immune response and lung damage: 1
    • aberrant immune response and lung injury: 1
    • activate immune cell and acute respiratory sars syndrome: 1
    • acute respiratory distress syndrome and additional therapeutic option: 1, 2, 3
    • acute respiratory distress syndrome and low airway: 1, 2, 3, 4, 5, 6
    • acute respiratory distress syndrome and low mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome and low respiratory tract: 1, 2
    • acute respiratory distress syndrome and lung biopsy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute respiratory distress syndrome and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory sars syndrome and additional therapeutic option: 1
    • acute respiratory sars syndrome and low airway: 1, 2, 3, 4
    • acute respiratory sars syndrome and low mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory sars syndrome and low respiratory tract: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute respiratory sars syndrome and lung biopsy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute respiratory sars syndrome and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory sars syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25